MyFinsight
Home
Blog
About
Contact
Download
Download image
Maturities of marketable
securities
$43,500,000
Sale of common stock
under at-the-market...
$4,588,687
Net cash provided by
(used in) investing...
$18,097,249
Net cash provided by
financing activities
$4,588,687
Canceled cashflow
$25,402,751
Net (decrease)
increase in cash and cash...
-$764,027
Canceled cashflow
$22,685,936
Grant receivable
-$1,827,238
Stock-based compensation
expense
$1,448,634
Accrued expenses and
other liabilities
$834,157
Prepaid expenses and
other current assets
-$638,355
Purchase of marketable
securities
$25,402,751
Net cash used in
operating activities
-$23,449,963
Canceled cashflow
$4,748,384
Net loss
-$26,966,367
Accretion of discount on
marketable securities, net
$854,077
Deferred offering costs
$310,581
Accounts payable
-$67,322
Back
Back
Cash Flow
source: myfinsight.com
CervoMed Inc. (CRVO)
CervoMed Inc. (CRVO)